


In the Claims

1. (Currently Amended) A serine protease inhibitor having the formula (I),




OK to  
Enter  
3/2/05  
in which

J is H, R<sup>1</sup>, R<sup>1</sup>-O-C(O)-, R<sup>1</sup>-C(O)-, R<sup>1</sup>-SO<sub>2</sub>-, R<sup>3</sup>OOC-(CHR<sup>2</sup>)<sub>p</sub>-,  
(R<sup>2a</sup>, R<sup>2b</sup>)N-CO-(CHR<sup>2</sup>)<sub>p</sub>- or Het-CO-(CHR<sup>2</sup>)<sub>p</sub>-;

Z is an amino-acid of the formula -NH-CHR<sup>1</sup>-C(O)-,  
-NR<sup>4</sup>-CH((CH<sub>2</sub>)<sub>q</sub>C(O)OR<sup>1</sup>)-C(O)-, -NR<sup>4</sup>-CH((CH<sub>2</sub>)<sub>q</sub>C(O)N(R<sup>2a</sup>, R<sup>2b</sup>))-C(O)-,  
-NR<sup>4</sup>-CH((CH<sub>2</sub>)<sub>q</sub>C(O)Het)-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic,  
D-1-Piq, D-3-Piq, ~~glutanyl~~ glutamyl or a (C<sub>1</sub>-C<sub>6</sub>) alkylester thereof;

E is -NR<sup>2</sup>-CH<sub>2</sub>- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R<sup>1</sup> is selected from (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF<sub>3</sub> or halogen, and